Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for ...

Novo Nordisk said it's ending its collaboration due to concerns with Hims & Hers the company's sales and promotion of cheap ...

Shares in Novo Nordisk fell as much as 3.5% on Monday after detailed trial data on its experimental obesity drug CagriSema ...

Shares in Denmark's pharmaceutical giant Novo Nordisk ( NVO 0.63%) were lower by 4% as of 11 a.m. ET today. The move comes as ...

This morning, the Danish pharmaceutical giant Novo Nordisk announced the abrupt end of its brief partnership with telehealth ...

Hims & Hers Health shares tumbled nearly 35% Monday after Novo Nordisk said it is pulling out of its partnership with the ...

Novo Nordisk said on Monday it would halt its collaboration with U.S. telehealth company Hims & Hers Health over the ...

Novo Nordisk’s new weight-loss drug helped patients lose even more weight on average than its current Wegovy blockbuster ...

NVO ends its deal with HIMS over safety concerns tied to compounded Wegovy, hitting patient access and market share plans.

Novo Nordisk’s next-gen weight loss drug and Zepbound “seem fairly equal to me,” one expert says after release of new ...

The effect of Novo Nordisk’s amycretin injections on body weight showed no signs of plateauing after 36 weeks, suggesting the ...

Novo Nordisk has rebounded strongly in 2025, backed by solid financials despite earlier setbacks and competitive risks. See ...